Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

Background: The recently developed antiandrogen, Enzalutamide (Enz), has reformed the standard of care for castration resistant prostate cancer (CRPC) patients. However, Enz-resistance inevitably emerges despite success of Enz in prolonging CRPC patients’ survival. Here we found that Enz-resistant p...

Full description

Bibliographic Details
Main Authors: Hua Xu, Yin Sun, Chi-Ping Huang, Bosen You, Dingwei Ye, Chawnshang Chang
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
ABT263
androgen receptor
ARv7
Enzalutamide
prostate cancer
Online Access:https://www.mdpi.com/2072-6694/12/4/831

Internet

https://www.mdpi.com/2072-6694/12/4/831

Similar Items